Glutathione‐Bioimprinted Nanoparticles Targeting of N6‐methyladenosine FTO Demethylase as a Strategy against Leukemic Stem Cells

Abstract The N6‐methyladenosine (m 6 A) demethylase FTO plays an oncogenic role in acute myeloid leukemia (AML). Despite the promising recent progress for developing some small‐molecule FTO inhibitors, the clinical potential remains limited due to mild biological function, toxic side effects and low sensitivity and/or specificity to leukemic stem cells (LSCs). Herein, FTO inhibitor‐loaded GSH‐bioimprinted nanocomposites (GNPIPP12MA) are developed that achieves targeting of the FTO/m 6 A pathway synergized GSH depletion for enhancing anti‐leukemogenesis. GNPIPP12MA can selectively target leukemia blasts, especially LSCs, and induce ferroptosis by disrupting intracellular redox status. In addition, GNPIPP12MA increases global m 6 A RNA modification and decreases the transcript levels in LSCs. GNPIPP12MA augments the efficacy of the PD‐L1 blockade by increasing the infiltration of cytotoxic T cells for enhanced anti‐leukemia immunity. This study offers insights for a GSH‐bioimprinted nanoplatform targeting m 6 A RNA methylation as a synergistic treatment strategy against cancer stem cells that may translate to clinical applications.